Merck (MRK) stock surged 12.12% after positive Phase 3 melanoma trial results with Moderna showed improved survival rates for intismeran plus KEYTRUDA. The post Merck & Company (MRK) Stock Soars 12% Following Breakthrough Melanoma Trial Results appeared first on Blockonomi.